Business
NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences
NEWPORT BEACH, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (“PMGC”), today announced a progress update to the anticipated completion timeline for Phase III of its AI Development Program with strategic partner Yuva Biosciences, Inc. (“Yuva Biosciences”). On December 17, 2025, Northstrive Biosciences announced the initiation of Phase III, which was expected to last approximately 6 to 9 weeks. N
About this update from Pmgc Holdings Inc.
[{"type":"image","alt":"PMGC Holdings Inc.","displaySize":"","headline":null,"caption":"PMGC Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":243,"url":"https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FeIekmuAEqql.btYh_OPxw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/546741842ddd656c130df2366fbdd9a7","width":300,"height":243}},"lazy":false},{"type":"text","content":"NEWPORT BEACH, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (“PMGC”), today announced a progress update to the anticipated completion timeline for Phase III of its AI Development Program with strategic partner Yuva Biosciences, Inc. (“Yuva Biosciences”).","length":358,"tagName":"p"},{"type":"text","content":"On December 17, 2025, Northstrive Biosciences announced the initiation of Phase III, which was expected to last approximately 6 to 9 weeks.","length":139,"tagName":"p"},{"type":"text","content":"Northstive Biosciences has been advised that Yuva Biosciences has an improved sixth-generation classifier models, representing a significant advancement in screening accuracy and sensitivity which will be applied to the Phase III study. These upgraded models enable a more refined selection of candidate compounds and a more comprehensive evaluation during the in-vitro validation stage.","length":387,"tagName":"p"},{"type":"text","content":"In light of these improvements, NorthStrive Biosciences has been advised by Yuva Biosciences that the Phase III results are expected to be available in Q2 2026. Yuva Biosciences expects that extended timeline will result in more robust, reliable, and informative results to support downstream development efforts.","length":313,"tagName":"p"},{"type":"text","content":"Northstrive Biosciences does not have control over the anticipated timeline provided by Yuva Biosciences, which remains subject to change and may occur before or after the currently expected date.","length":196,"tagName":"p"},{"type":"text","content":"About Yuva Biosciences, Inc.","length":28,"tagName":"p"},{"type":"text","content":"Yuva Biosciences, Inc. is a mitochondrial sciences AI company that uses advanced ...